問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

1738Cases

2015-06-02 - 2019-11-30

Phase II

A Phase 2, multicenter, randomized, double-blind study of ficlatuzumab plus erlotinib versus placebo plus erlotinib in subjects who have previously untreated metastatic, EGFR-mutated non-small cell lung cancer (NSCLC) and BDX004 Positive Label.

  • Condition/Disease

    NSCLC

  • Test Drug

    Ficlatuzumab (AV-299),

Participate Sites
8Sites

Terminated7Sites

夏德椿
China Medical University Hospital-Taipei

未分科

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2014-04-22 - 2017-10-04

Phase III

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 26-WEEK MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN ASIAN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MONOTHERAPY

  • Condition/Disease

    TYPE 2 DIABETES

  • Test Drug

    Ertugliflozin (MK-8835/PF-04971729)

Participate Sites
11Sites

Terminated11Sites

2017-04-25 - 2019-12-31

Others

An Open-label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients with Advanced Solid Tumor Malignancies

  • Condition/Disease

    solid tumor

  • Test Drug

    Sym015

Participate Sites
6Sites

Recruiting2Sites

Terminated3Sites

邱昌芳
China Medical University Hospital-Taipei

未分科

2016-11-01 - 2022-02-28

Phase III

A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer

  • Condition/Disease

    Metastatic Colorectal Cancer

  • Test Drug

    LGX818 ( Encorafenib) , MEK162( Binimetinib)

Participate Sites
8Sites

Terminated6Sites

王照元
Kaohsiung Municipal Gangshan Hospital

未分科

邱昌芳
China Medical University Hospital-Taipei

未分科

2013-08-05 - 2015-11-30

Phase III

A Phase 3b, Multicenter, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1, 2, 3 and 6 HCV Infection and in Treatment-Experienced Subjects with Chronic Genotype 2 HCV Infection

  • Condition/Disease

    HCV Infection

  • Test Drug

    Sofosbuvir

Participate Sites
13Sites

Terminated13Sites

2019-04-11 - 2021-09-30

Phase II

A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression.

  • Condition/Disease

    Gastric Cancer / Gastro-esophageal Junction (GEJ) Cancer

  • Test Drug

    Zolbetuximab (IMAB362)

Participate Sites
3Sites

Recruiting2Sites

白禮源
China Medical University Hospital-Taipei

未分科

2017-06-30 - 2022-07-29

Phase III

A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive Brivaracetam in subjects (≥16 to 80 years of age) with partial seizures with or without secondary generalization

  • Condition/Disease

    adjunctive treatment in subjects (>=16 to 80 years of age) with ​partial seizures with or without secondary generalization

  • Test Drug

    BRIVARACETAM®, tablets for oral administration

Participate Sites
6Sites

Recruiting1Sites

Terminated5Sites

2016-08-08 - 2019-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2021-11-01 - 2027-09-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-09-01 - 2026-06-30

Phase III

A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Quadrivalent Influenza Vaccine in Adults ≥65 Years of Age

  • Condition/Disease

    Influenza, Human

  • Test Drug

    Fluad Tetra

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

1 145 146 147 148 149 174
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB